CAR-T– tag –
-
Kincell Bio Inaugurates and Expands State-of-the-Art GMP Cell Therapy Manufacturing Facilities in Gainesville and Research Triangle Park
Kincell Bio USA Overview Kincell Bio has opened and expanded GMP cell therapy manufacturing facilities in Gainesville, Florida, and Research Triangle Park, North Carolina, designed to support both autologous and allogeneic cell therapies... -
EU-Funded S.O.L.A.R.I.S. Project Launched to Enhance Scalability, Efficiency, and Sustainability of CAR T Cell Manufacturing Across Europe
Green Elephant Biotech Germany Overview The EU-funded S.O.L.A.R.I.S. Project has commenced with 13 partners, including Green Elephant Biotech and Miltenyi Biotec, aiming to develop and implement new approaches for scalable, efficient, an... -
Umoja Biopharma Secures FDA IND Clearance for UB-VV400, First-in-Industry CD22-Targeted In Vivo CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies
Umoja Biopharma (Press Release) USA Overview Umoja Biopharma has received FDA Investigational New Drug (IND) clearance for UB-VV400, a CD22-targeted in vivo CAR T cell therapy candidate for relapsed/refractory B-cell malignancies. This m... -
Kincell Bio Unveils Scalable Allogeneic Cell Therapy Manufacturing Platform for Large-Scale Production with Closed-System Automation
Kincell Bio USA Overview Kincell Bio has launched a scalable allogeneic cell therapy manufacturing platform designed for large-volume production, efficient cell expansion, and closed-system automation. This platform supports diverse cell... -
Eli Lilly Acquires Kelonia Therapeutics for $7 Billion, Bolstering Gene Therapy with In Vivo CAR-T Generation Technology
DCAT Value Chain Insights USA Overview Eli Lilly announced the acquisition of Kelonia Therapeutics, a clinical-stage biopharma specializing in in vivo gene delivery, for $7 billion, including $3.25 billion upfront. Kelonia's "iGPS" techn... -
Kincell Bio Strengthens GMP Manufacturing for Autologous & Allogeneic Cell Therapies Across Diverse Modalities from US Two Sites
Kincell Bio USA Overview Kincell Bio announced enhanced GMP manufacturing services for both autologous and allogeneic cell therapy programs, leveraging two advanced facilities in Gainesville, Florida, and Research Triangle Park, North Ca... -
Jordan Advances Global CAR-T Access with High-Efficiency Point-of-Care Manufacturing Using CliniMACS Prodigy
ASCO Publications Jordan Overview In a significant step towards democratizing advanced cell therapies, point-of-care manufacturing of anti-CD19.1 CAR-T cells using the Miltenyi CliniMACS Prodigy system was successfully demonstrated in Jo... -
MD Anderson Reports 70% Response Rate with Novel Claudin-18.2-Targeted CAR-T Cell Therapy for Intractable Kidney Cancer
MD Anderson Newsroom USA Overview Researchers at MD Anderson Cancer Center announced a 70% objective response rate (ORR) in an early-phase clinical trial of a novel CAR-T cell therapy targeting Claudin-18.2 for patients with metastatic r... -
Chivanta Analysis: Allogeneic CAR-T Surpasses Autologous in Scalable Manufacturing and Immediate Availability, Spotlighting Fate Therapeutics’ iPSC Platform
Chivanta USA Overview Chivanta's analysis indicates allogeneic CAR-T therapies hold significant advantages over autologous CAR-T, particularly in scalable manufacturing, immediate availability, and product consistency. Companies like All... -
Vector BioMed’s LENTIVERSE™ Platform Accelerates CAR-T Manufacturing from Gene Sequence to Clinic-Ready in Under 12 Months
Vector BioMed USA Overview Vector BioMed has launched LENTIVERSE™, a lentiviral vector platform designed to dramatically accelerate CAR-T cell therapy manufacturing, aiming for completion from gene sequence to clinic-ready in less than 1...
